Abstract. Tanshinone ⅡA (TⅡA) is widely used for the treatment of a number human diseases, including diabetic nephropathy (DN) (1). The present study was performed to examine the role of the transforming growth factor β (TGFβ)/p65 pathway under TⅡA treatment in a glomerular mesangial cell model of DN. Firstly, it was identified that TⅡA inhibited the proliferation of HBZY-1 cells, while simultaneously suppressing the expression of TGFβ and p65. In addition, glucose-induced HBZY-1 cells were treated with TⅡA, si-TGFβ and si-p65. The results revealed that si-TGFβ or si-p65 were able to inhibit the proliferation of HBZY-1 cells as well. Finally, the expression of TGFβ and p65 in a rat model of DN treated with TⅡA was detected. The results demonstrated that renal hypertrophy and 24 h urinary protein excretion were ameliorated in TⅡA-treated rats with DN. Furthermore, it was revealed that the protein levels of TGFβ and p65 were decreased in the DN rats following TⅡA treatment. In conclusion, the present study demonstrated that TGFβ and p65 were activated by TⅡA in HBZY-1 cells. In addition, the expression of TGFβ and of p65 was downregulated in rats with DN treated with TⅡA.
Introduction
Diabetic nephropathy (DN) is characterized functionally by glomerular hyperfiltration and proteinuria, and histologically by the expansion of the glomerular mesangium, which is associated with the loss of renal function. The pathological changes in the kidney include increased glomerular basement membrane thickness, microaneurysm formation and mesangial nodule formation (Kimmelsteil-Wilson bodies) (1) (2) (3) (4) . A total of >30% of diabetes mellitus patients develop clinically evident DN, which becomes a major cause of end-stage renal disease (ESRD) worldwide (1, 3) . Its molecular pathogenesis is therefore becoming the target of a growing number of studies. Numerous factors have been reported to be associated with the development of DN and a large number of investigations are involved in therapeutic studies of the condition (4-7). One study revealed that treatment with vildagliptin + telmisartan controlled blood pressure, renovascular structural and biochemical parameters in diabetic neuropathy rats (4). Endo et al (8) performed a randomized, open trial on 162 type 2 diabetic patients and found that probucol suppressed the progression of DN and renal dysfunction events.
Tanshinone ⅡA (TⅡA) is a major phenanthrene-quinone isolated from Salvia miltiorrhiza Bunge, which is a Traditional Chinese Medicine (TCM) that is commonly used in various diseases and types of cancer (9) (10) (11) (12) . More importantly, a study by Kim et al (13) demonstrated that TⅡA has protective effects during the progression of DN and may be a potential drug candidate for the prevention of DN. As a multi-functional agent in TCM, TⅡA has a fundamental role in cellular responses to extracellular stimuli. For example, TⅡA protects cardiomyocytes in part through B-cell lymphoma 2/B-cell lymphoma 2-associated X protein and Akt-signaling pathways (14) (15) , is able to produce an inhibitory effect on the sterol regulatory element-binding transcription factor 1 pathway through the phosphoinositide 3-kinase/Akt signaling pathway (16) and significantly inhibits the expressions of numerous factors, including transforming growth factor β (TGFβ), in a rat model of DN (13) . However, only the primary action of TⅡA on DN has been studied, and the mechanisms underlying how TⅡA ameliorates DN require further elucidation.
There is an increasing amount of evidence that TGF-β induces and promotes inflammatory responses via activation of nuclear factor (NF)-κB in various diseases. In one study, TGF-β induced p65 acetylation to enhance bacteria-induced NF-κB activation (17) . Several studies have also indicated that TGF-β-Smad signaling mediates the activation of NF-κB in human airway epithelial cells (18) (19) . In addition, the clinical and pathological aspects of diabetic neuropathies are associ-ated with inflammatory phenomena (20) (21) . Therefore, the underlying mechanism of the activity of TIIA on DN may proceed via the TGFβ/p65 pathway. It was hypothesized that TⅡA may ameliorate DN by regulating TGF-β and p65. The present study aimed to investigate the functions of TGF-β and p65 during TⅡA therapy of DN using glucose-induced HBZY-1 cells.
Materials and methods
TⅡA treatment. TⅡA was purchased from Nanjing Zelang Medical Technological Co. Ltd (Jiangsu, China). The rat mesangial HBZY-1 cell line was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). The cells were cultured in RPMI-1640 (Gibco-BRL, Carlsbad, CA, USA) medium containing 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) under standard conditions (37˚C, 5% CO 2 ). The HBZY-1 cells were seeded in 96-well plates at 2.0x10 4 cells/well, and were cultured in 100 µl Dulbecco's modified Eagle's medium (DMEM) with or without high glucose (HG) and TⅡA. To determine the safe dosages of TⅡA to be used in further experiments in this study, the cells were randomly divided into six groups: i) Control; ii) high glucose (HG, 30 mmol/l); iii) HG + TⅡA (10 µM); iv) HG + TⅡA (20 µM); v) HG + TⅡA (40 µM) and vi) HG + TⅡA (80 µM). At 48 h following treatment with TⅡA, the cell viability was examined by the MTT assay.
Small interfering (si)RNA transfection. HBZY-1 cells were plated onto six-well plates (1x10 5 cells/well), maintained in DMEM containing 10% FBS for 12 h and transfected with a mixture containing Opti-MEM, 8 µl/well Lipofectamine™ 2000 (Invitrogen, San Diego, CA, USA) and either 0.5 µg/well scrambled siRNA (mock) or siRNAs (smart pool; Guangzhou RiboBio Co., Ltd., Guangzhou, Guangdong, China) for 6 h. The sequences of these siRNAs are listed in Table I . To detect the function of TGFβ and p65 in the HBZY-1 cells induced by HG, the cells were randomly divided into four groups: i) Control, ii) HG + mock; iii) HG + si-TGFβ; and iv) HG + si-p65. Following 48 h, the cell viability was examined by the MTT assay.
MTT assay. The HBZY-1 cells treated with or without HG, siRNA or TⅡA were collected and resuspended in 100 µl DMEM. A total of 20 µl MTT (5 mg/ml) was added, followed by incubation for 4 h at 37˚C. Finally, the samples were recorded at 490 nm using a microplate reader. The wells with only MTT served as blank controls. At least three independent experiments were performed.
Animals. Male Sprague Dawley (SD) rats (6-8 weeks old; weighing, 180-200 g) were obtained from the Guangdong Medical Laboratory Animal Center (Guangdong, China). The rats were divided into three groups: Normal control rats (n=8), DN rats (n=8) and TⅡA rats (n=8). DN and TⅡA rats were injected intraperitoneally with 45 mg/kg streptozotocin (STZ; Sigma, St. Louis, MO, USA), while the normal control rats received physiological saline (PS). Following seven weeks, the TⅡA rats were administered an intramuscular injection, at a dose of 8 mg/kg, of TⅡA daily for another three weeks, whereas the other rats received PS only. All of the animals were fed with high-fat food. After the animals were sacrificed, fresh kidney samples were stored in formaldehyde solution for histopathological observation. The remaining kidneys were stored at -80˚C for later analysis. The experimental procedure was approved by the Animal Experimentation Ethics Committee at The Guangzhou University of Chinese Medicine (Guangzhou, Guangdong, China).
Urine analyses. All of the animals were housed in metabolic cages for 24 h to obtain urine at seven weeks (one day prior to TⅡA treatment) and 10 weeks (one day prior to sacrifice) for the measurement of urine protein. The 24 h urinary protein excretion was assessed by the Coomassie brilliant blue method.
Histopathology. The cell morphology was examined in formalin-fixed, paraffin-embedded kidney sections (5 µm) stained with hematoxylin-eosin (H&E) (22). The histopathological scores were examined by glomerular mesangial expansion, mesangial matrix increase, interstitial mononuclear cells and extracellular matrix accumulation. Histological analysis was performed using a light microscope (Leica DM400 B, Bannockburn, IL, USA).
Quantitative polymerase chain reaction (qPCR).
Total RNA was extracted from the frozen kidney samples using the TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) following the manufacturer's instructions. The mRNA expression of TGFβ and p65, and β-actin was detected by qPCR utilizing a 7500 detector (ABI Prism 7500; Applied Biosystems, Foster City, CA, USA) according to manufacturer's instructions. PCR was performed with 100 ng total RNA using one-step SYBR PrimeScript RT-PCR kit (TakaRa, Tokyo, Japan) as follows: 42˚C for 5 min, 94°C for 10 sec followed by 40 cycles at 94˚C for 5 sec, 60˚C for 35 sec, with a final extension at 72˚C for 5 min. The primers used in the present study were as follows: TGFβ forward 5'-TGCTCTTGTGACAGCAAAGATAA-3' and reverse 5'-CTCTGTGGAGCTGAAGCAATAGT-3'; p65 forward 5'-CACCAAAGACCCACCTCACC-3' and reverse 5'-GGACCGCATTCAAGTCATAGTC-3'; β-actin forward 5'-GACAGGATGCAGAAGGAGATTACT-3' and reverse 5'-TGATCCACATCTGCTGGAAGGT-3' . The gene expression of interest was determined using the 2 -ΔΔ CT method (23) . The expression levels of all the transcripts were normalized to that of the housekeeping gene β-actin in the same tissue.
Western blot analysis. The proteins extracted from kidney tissues were examined using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA) and analyzed by western blot analysis. Antibodies used in the present study included: Rabbit polyclonal TGF-β (sc-146, diluted by 1:1,000), p65 (sc-101749, diluted by 1:2,000) and β-actin (sc-130657, diluted by 1:5,000). All antibodies were purchased from Santa Cruz (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Statistical analysis. The presented data were analyzed using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance was used to analyze the intergroup differences. The differences between the groups were compared using a t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

TⅡA inhibits HBZY-1 cell proliferation.
The effects of TⅡA on HBZY-1 cell proliferation were investigated using the MTT assay. Firstly, it was identified that the proliferative ability of the HBZY-1 cells treated with HG was slightly increased compared with that of the control group (although P>0.05). TⅡA inhibited the HG-induced HBZY-1 proliferation in a concentration-dependent manner. The data revealed that, following 48 h, TⅡA at 20 and 40 µΜ (P<0.05) as well as 80 µΜ (P<0.01) had a significant growth-inhibitory effect on the HBZY-1 cells (Fig. 1) .
TGFβ and p65 are suppressed by TⅡA in HBZY-1 cells.
Previous studies demonstrated that TGFβ and NF-κB increased in DN and had a key role in cell proliferation (24) . Therefore, next, the effects of TⅡA on TGFβ and NF-κB in HBZY-1 cells were examined using qPCR. As demonstrated in Fig. 2 , TGFβ and p65 were significantly upregulated in the HG-induced group compared with the control cells. However, TⅡA significantly inhibited the increase in TGFβ and p65 in the HBZY-1 cells induced by high glucose. This result may indicate that TGFβ and p65 were involved in the process by which TⅡA inhibited HBZY-1 cell proliferation.
si-TGFβ and si-p65 inhibit the proliferation of glucose induced HBZY-1 cells.
To determine whether TGFβ and p65 were able to inhibit HBZY-1 cell proliferation, their functions were investigated using RNA interference and subsequent MTT assay. qPCR data demonstrated that TGFβ and p65 were significantly inhibited by the designed si-TGFβ and si-p65 separately (Fig. 3A) . Of note, the MTT assay revealed that the knockdown of either TGFβ or p65 significantly inhibited HBZY-1 cell proliferation as compared with the HG-only treated group (Fig. 3B) . The above data suggested that TGFβ and p65 were necessary for HBZY-1 proliferation. TGFβ and p65 may therefore be involved in the intracellular mechanisms underlying the effect of TⅡA on HBZY-1 cell proliferation.
Therapeutic effect of TⅡA on the established DN rat. To determine the efficiency of TⅡA therapy in vivo, DN rat models A B induced by STZ were established. The 24 h urinary protein excretion of the DN rats and control rats was detected. In the DN rats group, the average 24 h urinary protein excretion reached 365 mg following STZ injection for seven weeks and then decreased to 247 mg during the subsequent physiological saline treatment over three weeks. However, in the TⅡA therapy group, a more significant reduction in the average 24 h urinary protein excretion was identified, from 503 mg to 161 mg during the TⅡA treatment over three weeks. This data demonstrated that TⅡA contributed to a larger decrement of average 342 mg urinary protein compared with 118 mg in the rats that received PS (Fig. 4B) . Furthermore, the morphological changes of the kidney were also examined. The kidney sections were stained with H&E for histochemical determination of the renal compartments. The DN rats developed renal lesions that consisted of an increasing glomerular mesangial matrix accumulation. In the TIIA treatment group, a moderate decrease in mesangial cellularity and hypertrophy of mesangial cells compared with control DN rats was observed (Fig. 4A) .
TⅡA inhibits the expression of TGFβ and p65 in DN rats. Since TGFβ and p65 are functional during the progression of DN in rats, next, whether they were involved in the beneficial effects of TⅡA therapy was investigated. The effects of TⅡA on the protein expression levels of TGFβ and p65 in the rat kidneys were assessed by western blot analysis. As demonstrated in Fig. 4C , the western blot results indicated that both TGFβ and p65 proteins were firstly upregulated in DN rats induced by STZ compared with normal control rats. However, following treatment of the DN rats with TⅡA for three weeks, it was identified that TGFβ and p65 levels in the kidney decreased compared with those in the DN rats treated with PS.
Discussion
DN is a progressive kidney disease characterized by long-term damage to the kidneys as a result of long-term poorly controlled diabetes. It is the most common diabetes mellitus in industrialized countries and >20 million people suffer from DN with a marked range of clinical manifestations (20) .
DN is considered to result from the interactions between a wide range of metabolic and haemodynamic factors that induce oxidative stress, polyol pathway flux, hexosamine flux and the accumulation of advanced glycated end-products (AGEs) (25, 26) . Therefore, therapeutic strategies that target DN have various mechanisms of action. The majority of previous treatment strategies have focused on the control of hyperglycemia. For example, prednisone was used at a dose of 0.75mg/kg/day, with daily control of glycaemia in patients (20) . The major focus of newer treatments appears to be on newer targets and is associated with glucose-dependent pathways as a result of diabetes. For example, drugs that inhibit the formation of AGEs include aminoguanidine, ALT-946, pyridoxamine and OPB-9195. In other studies, prostaglandins are suggested to be involved in the development of nephropathy. Treatment with cyclooxygenase-2 inhibitors, prostacyclin analogues and thromboxane A2 antagonists have also been demonstrated to be beneficial (6, (27) (28) (29) . The NFκB inhibitor pyrrolidine dithiocarbamate has been studied and has been demonstrated to confer renoprotection (30,31). Miyata et al (32) suggested that recent approaches targeting oxygen biology may offer novel treatments for DN. A study by Kim et al (13) demonstrated that TⅡA may have protective effects during the progression of DN and may be a potential drug for the prevention of DN. The present study revealed that renal hypertrophy and 24 h urinary protein excretion were partly recovered in TⅡA-treated rats, which further confirms that TⅡA ameliorated the pathological changes in DN rats.
Various theories have proposed that DN is associated with oxygen biology, including hypoxia, oxidative stress and dyserythropoiesis (32) . Previously, experimental studies demonstrated that a broad range of anomalies concerning the pathogenesis of DN, including proteinuria, genetics, race, hypoxia, ischemia and inflammation. Sustained inflammation may be the initiator to activate tissue fibrosis progression in DN (33, 34) . TGF-β has been demonstrated to have an essential role in fibrosis. Shaker and Sadik (35) demonstrated that serum TGF-β may also be a prognostic marker of DN. TGF-βs modulate the bodies' overall immune response by affecting different receptors and downstream signaling; for example, the inhibition of TGF-βs or the TGF-β-Smad signaling pathway has been demonstrated to exhibit anti-fibrotic effects (36) (37) (38) (39) (40) . In addition, Smads also interact with other signaling pathways, including NF-κB pathways (19, 41) . Liu et al (42) found that TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation were involved in a mouse model of obstructive nephropathy. Ka et al (24) demonstrated that the TGF-β/Smad and NF-κB signaling pathways were inhibited during therapy for type Ⅱ DN. Pioglitazone attenuates DN by downregulating TGF-β and NFκB in type II diabetic rats (43). Kim et al (13) identified that TGF-β was decreased in DN rat models treated with TⅡA. In the present study, the results revealed that TGFβ and p65 mRNA and protein expression were upregulated in DN rats and downregulated following treatment with TⅡA. Furthermore, similar results were observed in HBZY-1 cells. It was identified that TGFβ and p65 were suppressed by treatment with TⅡA. To further examine the interaction between TGFβ and p65 in this process, si-TGFβ or si-p65 were transfected into cells induced by HG. The MTT assay revealed that the knockdown of either TGFβ or p65 inhibited HBZY-1 cell proliferation, consistent with the effect of TⅡA. In conclusion, the results demonstrated that TGFβ and of p65 were downregulated by TⅡA in HBZY-1 cells. The renoprotective effect of TⅡA on DN may therefore proceed via the suppression of TGFβ and p65. These results may provide valuable information for the development of novel therapeutic strategies for DN.
